Today: 9 June 2026
Palantir (PLTR) Rockets 300% on AI Frenzy – Analysts Sound Bubble Alarm
22 October 2025
2 mins read

Palantir (PLTR) Rockets 300% on AI Frenzy – Analysts Sound Bubble Alarm

  • Stock Surge: Palantir’s shares have exploded roughly 3× in 2025, trading around $180 as of Oct 20–21, making it one of the year’s top-performing stocks . This rally is far above the S&P 500 and tech peers, propelled by red-hot AI investor enthusiasm.
  • Big AI & Defense Deals: The rally is underpinned by a string of blockbuster contracts. Notable wins include a $10 billion, 10-year U.S. Army IDIQ agreement, a £750–£1,500 million UK defense/AI partnership, a “game-changing” AI integration deal with Boeing Defense, plus new commercial AI tie-ups (e.g. a Snowflake AI-data partnership and OneMedNet healthcare deal) ts2.tech ts2.tech. These deals highlight Palantir’s deepening role in both government and enterprise AI.
  • Record Financials: Palantir’s fundamentals are finally catching up. Q2 2025 revenue jumped 48% YoY to ~$1.03 billion (its first $1B+ quarter) with $327 million GAAP profit, prompting management to raise 2025 revenue guidance to roughly $4.14–4.15 billion . U.S. government sales surged (42% of revs), and free cash flow is strong. Q3 guidance (~$1.083 billion) suggests growth is expected to continue .
  • Extreme Valuation: At ~$180 per share, Palantir’s market cap nears $400 billion, with forward price/sales >100× and P/E >200×, among the highest in market history ts2.tech reuters.com. By comparison, veteran AI chipmaker Nvidia trades in the 20s P/S. Critics warn these “unsustainable” multiples mean the stock is pricing in almost all future growth ts2.tech reuters.com.
  • Analyst Split & Targets: Wall Street is deeply divided. Bulls (e.g. Wedbush’s Dan Ives) hail Palantir as an “AI arms dealer” and see the boom as just beginning; Wedbush even envisions a $1 trillion market cap in the next few years reuters.com. Piper Sandler recently raised its 12-month price target to $201 (Overweight) ts2.tech. In contrast, skeptics (including short‑seller Citron) call the valuation “absurd”, pegging fair value near ~$65–$70 ts2.tech. Overall the consensus rating remains “Hold,” with targets ranging widely (roughly $100–$215, median ~$150–160 ts2.tech ts2.tech).
  • Bubble Concerns: Many market watchers now warn of an AI-fueled bubble. A Bank of America survey found AI stocks listed as the top global risk, and analysts note that tech valuations are at euphoric levels ts2.tech qz.com. Investing.co.uk analyst Christian Harris cautions that PLTR, trading at “over 200 times earnings,” could be among the first to fall if the AI buzz cools qz.com reuters.com.

With Q3 earnings (Nov. 3) looming, investors will watch whether Palantir can sustain this torrid pace or if profit-taking ensues. The company’s defense and AI momentum is real – Saxo’s Jacob Falkencrone notes Palantir is “becoming an indispensable partner for enterprises in the AI revolution” reuters.com – but the stock’s stratospheric run also leaves little margin for error. As one strategist put it, “the stock is trading at what is frankly an absolutely wild valuation”, so any slowdown or market rotation could trigger a sharp pullback qz.com.

Sources: Recent reports from TechStock² (TS2) and Reuters detail Palantir’s massive AI/defense contracts and financial beats . Analyst commentary comes from Reuters and Quartz interviews . All data is current as of late Oct. 2025.

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Stock Market Today

  • Alibaba Stock Falls 18% Amid Heavy AI Investment
    June 9, 2026, 10:38 AM EDT. Alibaba shares have dropped 18% year-to-date, weighed down by the company's aggressive spending on artificial intelligence (AI) initiatives. This investment strategy has raised concerns among investors about its impact on short-term profitability. The stock's decline outpaces broader market trends and highlights the risks tech giants face when prioritizing long-term innovation over immediate earnings. Analysts note the move reflects Alibaba's commitment to staying competitive in the evolving technology landscape despite near-term challenges.

Latest articles

Autozi Shares Jump 400%, Filing Flags Risks for AZI

Autozi Shares Jump 400%, Filing Flags Risks for AZI

9 June 2026
Autozi Internet Technology shares soared over 400% to $5.69 in early Nasdaq trading after a 10-for-1 share consolidation slashed its share count to about 4.49 million, but the surge contrasts with a 63.1% revenue drop, 82.5% plunge in gross profit, and widened net loss, with the company warning of “substantial doubt” about its ability to continue as a going concern.
Redwire Shares Slip After $500 Million Stock Offering Filed

Redwire Shares Slip After $500 Million Stock Offering Filed

9 June 2026
Redwire Corp shares plunged 6.5% to $17.37 after launching a $500 million at-the-market stock program, raising dilution risks for investors as the company seeks flexible funding despite recent record backlog and strong revenue growth; the drop contrasted with gains at other space stocks, highlighting investor concern over potential share issuance.
Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

9 June 2026
Nuvalent shares soared 38.9% to $122.93, just below GSK’s $124-a-share cash offer after the $10.6 billion buyout was announced, as investors bet on the deal closing with Nuvalent’s two lead lung-cancer drugs already under FDA review and a 40% premium to the last closing price driving the morning’s merger-arb trade.
Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
Beyond Meat Stock Skyrockets 400% – Bubble or Bargain?
Previous Story

Beyond Meat Stock Skyrockets 400% – Bubble or Bargain?

Texas Instruments (NASDAQ: TXN) Stock Surges on Dividend Hike, Then Plummets on Weak Outlook – Is a Slow Recovery Ahead?
Next Story

Texas Instruments (NASDAQ: TXN) Stock Surges on Dividend Hike, Then Plummets on Weak Outlook – Is a Slow Recovery Ahead?

Go toTop